scholarly journals Significance of Alliance Networks in Research and Development of Digital Health Products for Diabetes (Preprint)

JMIR Diabetes ◽  
10.2196/32446 ◽  
2021 ◽  
Author(s):  
Satoru Kikuchi ◽  
Kota Kodama ◽  
Shintaro Sengoku
Keyword(s):  
Research And Development ◽  
Digital Health ◽  
Alliance Networks ◽  
Health Products

Significance of Strategic Alliance in Research and Development of Digital Health Products for Diabetes (Preprint)

2021 ◽  
Author(s):  
Satoru Kikuchi ◽  
Kota Kodama ◽  
Shintaro Sengoku
Keyword(s):  
Research And Development ◽  
Medical Device ◽  
Digital Health ◽  
Information And Communications Technology ◽  
Smart Devices ◽  
Network Centrality ◽  
Eigenvector Centrality ◽  
Alliance Networks ◽  
The Relationship ◽  
The U.S

BACKGROUND Digital health has been advancing owing to technological progress by means of smart devices and artificial intelligence, amongst other developments. In the field of diabetes, especially, there are many active use cases of digital technology supporting the treatment of diabetes and improving lifestyle. In the innovation ecosystem, new alliance networks are formed not only by medical device companies and pharmaceutical companies, but also by information and communications technology (ICT) companies and start-ups. While understanding and utilizing the network structure is important to increase the competitive advantage of companies, there is a lack of previous research describing the structure of alliance networks and the factors that lead to their formation in digital health. OBJECTIVE The aim of this study was to explore the significance of alliance networks, focusing on digital health for diabetes, in effectively implementing processes, from the Research and Development (R&D) of products and/or services to their launch and market penetration. METHODS First, we listed the companies and contracts related to the digital health for diabetes, visualized the change in the number of companies and the connections between companies in each industry, and analyzed the overview of the network. Second, we calculated the degree, betweenness centrality, and eigenvector centrality of each company in each year. Next, we analyzed the relationship between network centrality and market competitiveness by using annual sales as a parameter of company competitiveness. We also compared the network centrality of each company by industry and/or headquarters location and analyze the characteristics of companies with higher centrality. Finally, we analyzed the relationship between network centrality and the number of products certified or approved by the U.S. Food and Drug Administration (FDA). RESULTS We found the degree centrality of companies was correlated with an increase in their sales; The betweenness and eigenvector centrality of medical device companies located in the U.S. were significantly higher than those outside the U.S; Finally, the degree, betweenness and eigenvector centralities were correlated with an increase in the number of Class III, but not of Class I nor II medical device products. CONCLUSIONS These findings give rise to new insights on the industry ecosystem for digital health and its requirement and expect a contribution to R&D practices in the field of digital health.

scholarly journals Characteristics and Classification of Technology Sector Companies in Digital Health for Diabetes

2021 ◽  
Vol 13 (9) ◽  
pp. 4839
Author(s):  
Satoru Kikuchi ◽  
Kota Kadama ◽  
Shintaro Sengoku
Keyword(s):  
Customer Value ◽  
Business Models ◽  
Digital Health ◽  
Information And Communications Technology ◽  
Smart Devices ◽  
Innovation Ecosystem ◽  
Alliance Networks ◽  
Technology Sector ◽  
Ibm Watson ◽  
Start Ups

In recent years, technological progress in smart devices and artificial intelligence has also led to advancements in digital health. Digital health tools are especially prevalent in diabetes treatment and improving lifestyle. In digital health’s innovation ecosystem, new alliance networks are formed not only by medical device companies and pharmaceutical companies but also by information and communications technology (ICT) companies and start-ups. Therefore, while focusing on digital health for diabetes, this study explored the characteristics of companies with high network centralities. Our analysis of the changes in degree, betweenness, and eigenvector centralities of the sample companies from 2011 to 2020 found drastic changes in the company rankings of those with high network centrality during this period. Accordingly, the following eight companies were identified and investigated as the top-ranking technology sector companies: IBM Watson Health, Glooko, DarioHealth, Welldoc, OneDrop, Fitbit, Voluntis, and Noom. Lastly, we characterized these cases into three business models: (i) intermediary model, (ii) substitute model, and (iii) direct-to-consumer model, and we analyzed their customer value.

scholarly journals Understanding uptake of digital health products: Methodology tutorial for a Discrete Choice Experiment using a Bayesian efficient design (Preprint)

2021 ◽  
Author(s):  
Dorothy Szinay ◽  
Rory Cameron ◽  
Felix Naughton ◽  
Jennifer A. Whitty ◽  
Jamie Brown ◽  
...  
Keyword(s):  
Discrete Choice Experiment ◽  
Discrete Choice ◽  
Choice Experiment ◽  
Stated Preference ◽  
Digital Health ◽  
Revealed Preferences ◽  
Quantitative Methodology ◽  
Efficient Design ◽  
Trade Offs ◽  
Health Products

UNSTRUCTURED Understanding the preferences of potential users of digital health products is beneficial for digital health policy and planning. Stated preference methods could help elicit individuals’ preferences in the absence of observational data. A discrete choice experiment (DCE) is a commonly used stated preference method; a quantitative methodology that argues that individuals make trade-offs when engaging in a decision by choosing an alternative of a product or service that offers the greatest utility, or benefit. This methodology is widely used in health economics in situations where revealed preferences are difficult to collect but is much less used in the field of digital health. This article outlines the stages involved in developing a discrete choice experiment. As a case study, it uses the application of a DCE for revealing preferences in targeting the uptake of smoking cessation apps. It describes the establishment of attributes, the construction of choice tasks of two or more alternatives, and the development of the experimental design. This tutorial offers a guide for researchers with no prior knowledge of this research technique.

Home Use Devices and SaMDs in Patient Self-Care: Concept to Develop Excellenct Products in Digital Health

2018 ◽  
Vol 7 (1) ◽  
pp. 189-194
Author(s):  
Peter Rasche ◽  
Laura Barton ◽  
Katharina Schäfer ◽  
Sabine Theis ◽  
Christina Bröhl ◽  
...  
Keyword(s):  
Healthcare System ◽  
Research Group ◽  
Digital Health ◽  
Self Care ◽  
Formal Concept ◽  
German Health ◽  
Health Products ◽  
German Healthcare System ◽  
Start Ups ◽  
Further Development

The German healthcare system is characterized by digital change. In recent years, a trend towards the entry of start-ups and medium-sized enterprises into this sector has developed. These types of companies in particular are facing enormous challenges due to the industry and the ongoing digital change. This article presents the fundamental developments and challenges of these companies. Further solutions developed by the Tech4Age research group are presented briefly. Finally, this article describes how these solutions can be integrated into a formal concept for the promotion and further development of SMEs and start-ups in the German health industry in order to enable them quickly and comprehensively for the development of excellent digital health products.

scholarly journals INTRODUCTION - Mechanism-based Development of Natural Products for Human Health

2013 ◽  
Vol 16 (2) ◽  
pp. 123
Author(s):  
Basil D Roufogalis ◽  
Arthur D Conigrave ◽  
Emanuel E Strehler
Keyword(s):  
Natural Products ◽  
Product Development ◽  
Research And Development ◽  
Natural Product ◽  
Mechanisms Of Action ◽  
Pharmaceutical Sciences ◽  
Special Issue ◽  
Active Components ◽  
Health Products ◽  
Natural Medicines

This Special Issue of the Journal of Pharmacy and Pharmaceutical Sciences arises from an inaugural conference on “Mechanism-Based Natural Product Development” held at Whistler Mountain, Canada on September 21-22, 2012. The aim of the conference was to bring together scientists from various disciplines to discuss the development of new therapeutic products from natural medicines based on mechanistic and related scientific studies. It provided an opportunity to explore new directions in natural medicine research and development, with the ultimate objective of leading to greater integration of natural and conventional synthetic pharmaceutical medicines for the health of the community worldwide. The concept for this conference and the Special Issue has come from the growing interest internationally in traditional and natural medicinal health products in recent years. It may, at first, appear surprising that developed countries are re-embracing natural product research and development. There are of course many reasons for this, including growing community interest in natural products providing improved health and wellbeing, the growing difficulty and cost of maintaining a pipeline of effective and, above all, safe new products for chronic diseases in the mainstream pharmaceutical industry, and the knowledge that many of our small drug pharmaceutical medicines have come from plants and other organisms. But as traditional natural product medicines increasingly enter the mainstream, the call for evidence to support their use also grows louder. Essential to the acceptance of natural medicines are the validation of their traditional uses and identification, isolation and structural characterization of their active components, together with the elucidation of their mechanisms of biological action, adverse effects, and identification of their molecular targets. These requirements provide the focus of this Special Issue. Scientific investigation and development of new health products requires the joining together of many disciplines, including chemistry, pharmacology, pharmacognosy and cell and molecular biology, as well as integration with clinical medicine. Natural product medicines are expected to be multi-component and multi-targeted. Are they effective, safe and properly standardized in their existing formulations? Are there opportunities to isolate single active components for standardization and conventional drug discovery and development? Answering these questions requires collaboration between scientific disciplines focused on a common goal. In line with the aims of the conference, the Special Issue has incorporated review and original research articles related to mechanisms of action in a number of therapeutic areas, mostly from invited speakers at the Whistler conference. Other articles were unsolicited submissions to the Journal that satisfy the scope of the issue. Articles range from reports on efforts to work with traditional owners in the appropriate cultural context, to develop new therapeutics based on traditional literature, to discover new medicinal products, to develop new pharmaceuticals based on the isolation of active chemical components, to develop new methods of delivery, and to identify mechanisms of action. The medical 'territory' includes cancer, heart disease, diabetes and related chronic inflammatory diseases, pain pathways, deafness and infertility. Other articles investigate the quality and safety of products by the application of current analytical methods, the potential for interactions of natural products (e.g., cranberry) with pharmaceutical medicines and the variability of a selection of similar natural product medicines with regard to their contents of therapeutically beneficial and marker compounds, as claimed on the product labels. In addition, the issue includes the abstracts of posters that formed an important part of the conference, especially from postgraduate students and postdoctoral fellows. These are included as Proceedings. We are indebted to the scientists who willingly gave their time and resources to attend the Whistler conference and, in many cases, submitted manuscripts for inclusion in this Special Issue. The delegates and contributors came from many places, near and far, to make this inaugural conference on mechanism-based natural product development a success. Such a conference and the subsequent proceedings in the Special issue are not possible without the work of many. We thank the organizing and scientific committee for their support and valuable suggestions. A conference of this scope would not be possible without sponsorship; this includes especially the National Health Products Research Society of Canada, the Canadian Society for Pharmaceutical Sciences and several Universities. Major support, without program or editorial input, was provided by SOHO Flordis International (SFI). We commend them for believing in the quest for clinically proven and research-based products based on an understanding of underlying mechanisms. The support of Purapharm International is also gratefully acknowledged. We would like to dedicate this Special Issue to Professor Allan SY Lau of the University of Hong Kong, who contributed enthusiastically to the organization of the conference and its program, but was ultimately unable to attend due to his untimely passing. Professor Lau was a pioneer in the integration of natural and orthodox medical studies and his inspiration will be greatly missed. Basil D Roufogalis, Arthur D Conigrave and Emanuel E Strehler Co-Guest Editors

scholarly journals Digital health for the End TB Strategy: developing priority products and making them work

2016 ◽  
Vol 48 (1) ◽  
pp. 29-45 ◽  
Author(s):  
Dennis Falzon ◽  
Hazim Timimi ◽  
Pascal Kurosinski ◽  
Giovanni Battista Migliori ◽  
Wayne Van Gemert ◽  
...  
Keyword(s):  
Large Scale ◽  
Task Force ◽  
Digital Health ◽  
World Health ◽  
Electronic Learning ◽  
Country Level ◽  
Health Innovations ◽  
World Health Assembly Resolution ◽  
Health Products ◽  
Health Organization

In 2014, the World Health Organization (WHO) developed the End TB Strategy in response to a World Health Assembly Resolution requesting Member States to end the worldwide epidemic of tuberculosis (TB) by 2035. For the strategy's objectives to be realised, the next 20 years will need novel solutions to address the challenges posed by TB to health professionals, and to affected people and communities. Information and communication technology presents opportunities for innovative approaches to support TB efforts in patient care, surveillance, programme management and electronic learning. The effective application of digital health products at a large scale and their continued development need the engagement of TB patients and their caregivers, innovators, funders, policy-makers, advocacy groups, and affected communities.In April 2015, WHO established its Global Task Force on Digital Health for TB to advocate and support the development of digital health innovations in global efforts to improve TB care and prevention. We outline the group's approach to stewarding this process in alignment with the three pillars of the End TB Strategy. The supplementary material of this article includes target product profiles, as developed by early 2016, defining nine priority digital health concepts and products that are strategically positioned to enhance TB action at the country level.

scholarly journals How Can an AI Supported, Self-Assessment Tool Raise Standards of Digital Health Services During COVID-19 Emergency?

2021 ◽  
Author(s):  
Neja Samar Brenčič ◽  
Malcolm Fisk ◽  
Uroš Rajkovič
Keyword(s):  
Health Services ◽  
Social Services ◽  
Assessment Tool ◽  
Digital Health ◽  
Assessment Tools ◽  
Alternative Form ◽  
Self Assessment ◽  
Traditional Health ◽  
Health Products ◽  
Common Interests

It is understandable that digital health services are now being developed in the context of a global emergency. However, it is crucial that standards are in place for these services to support their operation in a way that accommodates common interests and objectives and recognises the level of their importance for all stakeholders involved (including service recipients or users). We believe that it is necessary to establish and maintain quality standards for digital health products and services in these conditions. Furthermore, even after the pandemic, the need to integrate digital health services into traditional health and social services will remain a priority. Therefore we consider whether multi-criteria, self assessment tools, supported with artificial intelligence, can raise standards of digital health services that are rapidly developing as a consequence of the COVID-19 pandemic. We believe that such digital services are no longer just an alternative form of health care. It follows that frameworks for the development of standards, accreditation and regulation must also be included as national (or supra-national) priorities. These will help ensure not only technological but also service quality.

Sign in / Sign up

Export Citation Format

Share Document